摘要
目的:调查接受化疗的肿瘤患者失眠的流行病学特征并分析失眠相关的危险因素。方法:应用自制的患者一般资料调查表、可能与睡眠相关的因素调查表及国际通用的ESS(爱泼沃斯嗜睡量表)、汉密尔顿抑郁调查表(HDI)及MDASI症状评估表对634例接受化疗的住院患者进行问卷调查。结果:77.3%的患者出现失眠,40.1%出现失眠综合征,37.2%仅出现失眠症状。年龄为50～60岁的患者更易出现失眠(P=0.002),肺癌患者出现失眠的比例最高。Logistic回归分析显示年龄、性别、家庭收入、医疗保险、合并疾病、化疗不良反应、抑郁、疼痛均与化疗患者出现失眠相关。结论:接受化疗的患者,失眠的发生率明显高于正常人群。与失眠相关的危险因素众多。
Objective： Investigation on the prevalence of sleeping disturbance and analyze the risk factors associated with the patients undergoing chemotherapy. Methods： Total 634 inpatients with chemotherapy were inquired with questionnaires of general information and correlation factors about dyssomnia and the Epworth Sleepiness Scale （ESS）, the Hamilton Depression Inventory （HDI） and M.D.Anderson Symptom Inventory （MDASI）. Results： 77.3% of the patients reported insomnia, 40.1% met the diagnostic criteria for insomnia syndrome, 37.2% of the patients with cancer reported insomnia symptoms, and Patients with cancer older at 50~60 years were signi？cantly more likely to experience either symptoms of insomnia or insomnia syndrome （P-0.002）. Patients with lung cancer reported the highest insomnia syndrome prevalence. Logistic regression analysis showed the age, gender, the annual household income, medical insurance, Complicated diseases, the adverse effects of chemotherapy, depression, pain were significantly different between good- sleepers and the patients with insomnia. Conclusion： The proportions of patients with cancer in this sample reporting insomnia was higher than the general population and the insomnia patients with chemotherapy is affected by many factors.
出处
《药品评价》
CAS
2012年第12期20-24,共5页
Drug Evaluation
关键词
睡眠障碍
失眠
化疗
影响因素
Sleeping disturbance
Insomnia
Chemotherapy
Effect factor
